Supra-inguinal Fascia Iliaca Compartment Block on Postoperative Management in Total Hip Arthroplasty by Posterior Approach

May 16, 2022 updated by: Jean François Brichant, University of Liege

Impact of Supra-inguinal Fascia Iliaca Compartment Block on Postoperative Opioid Consumption in Total Hip Arthroplasty Interventions by Posterior Approach

Find the impact of supra-inguinal fascia iliaca compartment block on postoperative pain management after total hip arthroplasty by posterior surgical approach

Study Overview

Detailed Description

ASA physical status 1, 2 and 3 patients scheduled to undergo elective surgery of total hip arthroplasty under spinal anesthesia.

The investigators would like to study the impact of supra-inguinal fascia iliaca block on postoperative pain management after total hip arthroplasty by posterior surgical approach. The principal investigator perform this block with ultrasound technique. The investigators also want to observe if this loco-regional new approach to fascia iliaca block could have influence on opioid side effects, postoperative nausea and vomiting, length of hospitalisation and first mobilisation side effects.

Study Type

Interventional

Enrollment (Actual)

86

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Liège, Belgium, 4000
        • CHU de Liege

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Adults patients scheduled to undergo elective surgery of total hip arthroplasty by posterior surgical aboard

Exclusion Criteria:

  • Patient refusal
  • Allergy to used medications or local infection.
  • Pregnancy
  • Obesity with body mass index > 35
  • History of chronic pain or fibromyalgia
  • Drug (opioids) addiction
  • Treatment with corticosteroids for more than 6 months
  • Severe kidney or liver diseases
  • Mental disorders or serious neurological diseases

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: Placebo
Placebo group: patients have multimodal analgesia without fascia-iliaca compartment block
Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump
Experimental: Fascia iliaca block
Patients in this arm have multimodal analgesia with supra-inguinal fascia iliaca compartment block before surgery
Patients in placebo group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump

Ultrasound guided loco-regional technique as described by Desmet et al. Fascia iliaca compartment block with in-plane 40 ml ropivacaine 0,375% injection between the ilio-psoas muscle and the internal oblique muscle.

Patients in SFICB group have classical multimodal approach to postoperative analgesia with morphine administration by PCA pump

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Opioid sparing
Time Frame: 48 hours after the intervention
Difference in cumulated morphine consumption in the first 48 hours after surgery
48 hours after the intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Opioid secondaries effects
Time Frame: 48 hours after the intervention
incidence of secondary effects related to morphine consumption
48 hours after the intervention
Pain management satisfaction: questionnaire
Time Frame: 48 hours after the intervention
pain management satisfaction score by IPO (International Pain Outcomes) questionnaire
48 hours after the intervention

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 16, 2020

Primary Completion (Actual)

September 1, 2021

Study Completion (Actual)

September 2, 2021

Study Registration Dates

First Submitted

August 31, 2020

First Submitted That Met QC Criteria

October 1, 2020

First Posted (Actual)

October 5, 2020

Study Record Updates

Last Update Posted (Actual)

May 17, 2022

Last Update Submitted That Met QC Criteria

May 16, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Arthropathy of Hip

Clinical Trials on Multimodal analgesia and PCA morphine pump

3
Subscribe